Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): Interim safety and efficacy results from a phase 1 study Meeting Abstract


Authors: Budde, L. E.; Sehn, L. H.; Assouline, S.; Flinn, I. W.; Isufi, I.; Yoon, S. S.; Kim, W. S.; Matasar, M. J.; Nastoupil, L. J.; Santiago, R.; Koh, Y.; Hernandez, G.; Li, C. C.; Kulkarni, P. R.; McCall, B.; McClellan, S.; Yin, S.; Gupta, V.; Chu, Y. W.; Bartlett, N. L.
Abstract Title: Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): Interim safety and efficacy results from a phase 1 study
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837601108
PROVIDER: wos
Notes: Meeting Abstract : 399 -- Source: Wos